EyePoint Pharmaceuticals, Inc.

NasdaqGM:EYPT 주식 보고서

시가총액: US$450.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

EyePoint Pharmaceuticals 미래 성장

Future 기준 확인 2/6

EyePoint Pharmaceuticals (는) 각각 연간 1% 및 44.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -92.3% 로 예상됩니다.

주요 정보

1.0%

수익 성장률

7.3%

EPS 성장률

Pharmaceuticals 수익 성장22.6%
매출 성장률44.6%
향후 자기자본 수익률-92.3%
애널리스트 커버리지

Good

마지막 업데이트07 Aug 2024

최근 미래 성장 업데이트

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19
Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05
Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13
These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14
Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17
Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely

Sep 24
EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely

Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Apr 02
Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?

Feb 22
How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?

수익 및 매출 성장 예측

NasdaqGM:EYPT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20269-218-136N/A8
12/31/202514-177-137N/A11
12/31/202442-127-115N/A8
6/30/202450-87N/AN/AN/A
3/31/202450-79-17-12N/A
12/31/202346-71-22N/A
9/30/202343-100912N/A
6/30/202337-1061214N/A
3/31/202340-102-64-62N/A
12/31/202241-102-67-65N/A
9/30/202242-78-71-69N/A
6/30/202241-77-64-64N/A
3/31/202239-67-55-55N/A
12/31/202137-58-50-50N/A
9/30/202133-54-28-28N/A
6/30/202139-42-19-19N/A
3/31/202134-44-14-13N/A
12/31/202034-45-15-14N/A
9/30/202036-40-32-32N/A
6/30/202023-52-48-48N/A
3/31/202026-51-60-60N/A
12/31/201920-57-57-57N/A
9/30/201914-58-56-56N/A
6/30/201912-75-53-53N/A
3/31/20196-98-42-42N/A
12/31/20185-86-34-33N/A
9/30/20183-80-28-28N/A
6/30/20183-53-22-22N/A
3/31/20183-25N/A-20N/A
12/31/20173-23N/A-20N/A
9/30/20178-17N/A-20N/A
6/30/20178-18N/A-20N/A
3/31/20177-19N/A-20N/A
12/31/20167-19N/A-20N/A
9/30/20161-24N/A-18N/A
6/30/20162-22N/A-16N/A
3/31/20162-20N/A-15N/A
12/31/20152-20N/A-15N/A
9/30/20152-19N/A10N/A
6/30/2015276N/A10N/A
3/31/2015268N/A11N/A
12/31/20142810N/A13N/A
9/30/20142811N/A-11N/A
6/30/20143-13N/A-11N/A
3/31/20144-13N/A-11N/A
12/31/20132-14N/A-11N/A
9/30/20132-13N/A-11N/A

애널리스트 미래 성장 예측

수입 대 저축률: EYPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: EYPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: EYPT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: EYPT 의 수익(연간 40.3% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: EYPT 의 수익(연간 40.3% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: EYPT (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견